Phase 2, randomized, quadruple-blind, parallel-assignment trial (NCT02411253) evaluating the efficacy and safety of low-dose IL-2 in preserving beta cell function in recent-onset T1D. Primary outcomes include change in C-peptide AUC, determined after a MMTT at month 12. The study duration is 24 months (63). The gene discussed is IL2; the disease is type 1 diabetes mellitus.